Study Comparing AEZS-108 to Doxorubicin as a Second Line Therapy of Endometrial Cancer
There is information about the upcoming study with AEZS 108 and Endometrial Cancer. The study lead investigator is Dr Miller @ UT Southwestern medical Center in Dallas, and Dr Gabra @ Imperial College in London. They have not started enrolling, but on the clinical Trial website, it states the study will start in March. There will be 500 patients in the study, and it will be open label. Lets hope for a favorable partnership that is comparable to Endocyte received with Merck last April.